for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Livzon Pharmaceutical Group Inc

1513.HK

Latest Trade

20.95HKD

Change

-0.25(-1.18%)

Volume

699,480

Today's Range

20.75

 - 

21.40

52 Week Range

15.42

 - 

23.46

As of on the Hong Kong Stock Exchange ∙ Minimum 15 minute delay

Pricing

Previous Close
21.20
Open
21.40
Volume
699,480
3M AVG Volume
21.66
Today's High
21.40
Today's Low
20.75
52 Week High
23.46
52 Week Low
15.42
Shares Out (MIL)
934.76
Market Cap (MIL)
25,718.19
Forward P/E
13.69
Dividend (Yield %)
5.01

Next Event

Q3 2019 Livzon Pharmaceutical Group Inc Earnings Release

Latest Developments

More

Livzon Pharmaceutical Says Fu Daotian Resigned As Executive Director And Vice President

Livzon Pharmaceutical's H1 Net Profit Up 16.7% Y/Y

Livzon Pharmaceutical Updates On JV Co Zhuhai Qi'ao Biotechnology

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Livzon Pharmaceutical Group Inc

LIVZON PHARMACEUTICAL GROUP INC. is a China based company principally engaged in the research and development, production and sales of pharmaceutical products. The Company's main products include western medicine preparation such as gastrointestinal drugs, cardiovascular drugs and antimicrobial drugs and gonadotrophin drugs, Chinese medicine preparation, active pharmaceutical ingredient and intermediates, diagnostic reagents and equipments. The Company distributes its products in the domestic market and to overseas markets.

Industry

Biotechnology & Drugs

Contact Info

Livzon Mansion

No.132, Guihua Road North, Gongbei

+86.756.8135888

http://www.livzon.com.cn

Executive Leadership

Baoguo Zhu

Chairman of the Board

Yanggang Tang

President, Executive Director

Desheng Tao

Vice Chairman of the Board

Guoxiang Xu

Vice President

Daihong Yang

Vice President

Key Stats

2.00 mean rating - 9 analysts
Sell
Hold
Buy
Revenue (MM, CNY)

2016

7.7K

2017

8.5K

2018

8.9K

2019(E)

9.9K
EPS (CNY)

2016

0.897

2017

4.769

2018

1.162

2019(E)

1.358
Price To Earnings (TTM)
14.81
Price To Sales (TTM)
2.51
Price To Book (MRQ)
1.68
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
7.91
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
12.48
Return on Equity (TTM)
8.29

Latest News

Latest News

CORRECTED-BRIEF-Livzon Pharmaceutical Unit's JV Livzon Biologics' Capital Will Be Boosted By 600 Mln Yuan (Feb 7)

* SAYS CAPITAL AT UNIT'S JV LIVZON BIOLOGICS WILL BE BOOSTED BY 600 MILLION YUAN ($94.94 million) Source text in Chinese: http://bit.ly/2nMWH27 Further company coverage: ($1 = 6.3201 Chinese yuan renminbi) (Reporting by Hong Kong newsroom)

BRIEF-Livzon Pharmaceutical Group Announces Proposed Cash Dividend Distribution & Share Issue

* RECEIVED NOTICE FROM SHAREHOLDER PROPOSING ISSUE OF 3 BONUS SHARES FOR EVERY 10 SHARES TO ALL SHAREHOLDERS

BRIEF-Livzon Pharmaceutical Group Says Joincare To Sell 49 PCT Equity Interests In Livzon Mab

* PROPOSES TO ENTER AGREEMENT PURSUANT TO WHICH JOINCARE TO SELL 49% EQUITY INTERESTS IN LIVZON MAB FOR RMB294 MILLION Source text for Eikon: Further company coverage:

REFILE-BRIEF-Livzon Pharmaceutical'ss Board Agrees Unit To Invest $30 Mln In Global Health Science Fund II

* SAYS BOARD AGREES UNIT TO INVEST $30 MILLION IN GLOBAL HEALTH SCIENCE FUND II, L.P. Source text in Chinese: http://bit.ly/2CVb0qK Further company coverage: (Reporting by Hong Kong newsroom)

BRIEF-Livzon Pharmaceutical Group receives subsidy of 12.8 mln yuan

* Says it received subsidy of 12.8 million yuan for injection internationalization and development related projects

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says Zhuhai-based biotechnology unit received drug clinical trial approval for drug named Recombinant Human anti-RANKL Monoclonal Antibody Solution for Injection

BRIEF-Livzon Pharmaceutical Co Announces Change In Shareholding Structure Of Livzon MABPharm

* CO & JOINCARE PHARMACEUTICAL INDUSTRY ENTERED FRAMEWORK AGREEMENT RELATING TO CAPITAL CONTRIBUTION TO LIVZON BIOLOGICS

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for Recombinant Humanized anti-PD-1 Monoclonal Antibody for Injection

BRIEF-Livzon Pharmaceutical's net profits up in Q3, Jan-Sept

* Says Q3 net profit up 1,719.2 percent y/y at 3.7 billion yuan ($556.85 million), 9-month net profit up 590.7 percent y/y at 4.2 billion yuan

BRIEF-Livzon Pharmaceutical sees FY net profit attributable between RMB4.32 bln - RMB4.48 bln

* Sees FY net profit attributable between RMB4.32 billion - RMB4.48 billion Source text for Eikon: Further company coverage:

BRIEF-Livzon Pharmaceutical Group units receive approval for drug clinical trials

* Says its units received drug clinical trials approval for drug, Triptorelin Acetate Microspheres for Injection

BRIEF-Livzon Pharmaceutical Group unit receives approval for drug clinical trial

* Says its unit received drug clinical trial approval for antineoplastic, Paclitaxel polymeric micelles for injection

BRIEF-Livzon Pharmaceutical Group says change of accounting policies

* Says it changes accounting policies regarding government subsidy, non-current assets, disposal groups and discontinued operations

BRIEF-Livzon Pharmaceutical sees Jan-Sept net profit attributable between RMB4.23 bln-RMB4.27 bln

* Sees Jan-Sept 2017 net profit attributable to rise 587.86 pct - 594.55 pct to RMB 4,228.7864 million-RMB 4,269.9288 million Source text for Eikon: Further company coverage: (bangalore.newsroom@thomsonreuters.com)

BRIEF-Livzon Pharmaceutical updates on releasing of pledged shares held by controlling shareholder

* Received notice from Topsino that Topsino released pledge of its 16.3 million H shares of co from Nanyang Commercial Bank Source text for Eikon: Further company coverage:

BRIEF-Livzon Pharmaceutical announces net profit attributable for HY ended 30 June 2017

* Preliminary net profit attributable for six months ended 30 June 2017 about rmb 490.9 million-rmb531.8 million versus rmb409.1 million last year Source text for Eikon: Further company coverage:

BRIEF-Livzon Pharma expects H1 net profit to rise 20-30 pct y/y

* Says it expects H1 net profit to rise 20-30 percent y/y to 490.9-531.8 million yuan ($72.20-$78.21 million)

BRIEF-Livzon Pharmaceutical Group elects chairman, vice chairman

* Says board elects Zhu Baoguo as chairman, Tao Desheng as vice chairman

BRIEF-Livzon Pharmaceutical Group to pay FY 2016 annual div on July 7

* Says it will pay FY 2016 dividend to shareholders of record on July 6

BRIEF-Livzon Pharma's unit signs medicine sales contract for 480.6 mln yuan

* Says unit signs medicine sales contract for 480.6 million yuan ($70.61 million)

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up